A clinical trial of BJ 005 in China
Latest Information Update: 18 Oct 2019
At a glance
- Drugs BJ 005 (Primary)
- Indications Cancer
- Focus Adverse reactions
Most Recent Events
- 18 Oct 2019 New trial record
- 11 Oct 2019 According to a CMAB Biopharma media release, CMAB Biopharma and BJ Bioscience Establish an Exclusive Strategic Partnership.Under this agreement, CMAB will provide a full range of CMC research and manufacturing services that meet the IND application requirements of both China and the United States. The strategic cooperation will support the clinical development of BJ-005 worldwide by BJ Bioscience and is based upon CMAB's award-winning CMC process development and manufacturing platform.